Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data...
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical...
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621...
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...
Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass.,...
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer...
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing...
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ...